相关实验视频
Updated: Sep 15, 2025

07:25
Assessing Murine Resistance Artery Function Using Pressure Myography
Published on: June 7, 2013
22.4K
向内皮SMAD4可以改善高血压小鼠内皮功能障碍
Jinzhao Yang1, Jiang-Yun Luo2, Hongyin Chen1
1School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China.
Journal of molecular and cellular cardiology
|July 14, 2025
概括
Smad4对于高血压引起的血管问题至关重要. 在内皮细胞中去除Smad4可以降低血压,改善血管功能,降低炎症和压力.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 高血压研究 高血压研究
背景情况:
- 内皮功能障碍显著导致高血压.
- TGF-β/BMP信号通路的失调会导致血管病变的恶化.
- 在高血压相关的血管炎症和功能障碍中SMAD4的具体作用尚不清楚.
研究的目的:
- 研究SMAD4在高血压期间内皮功能障碍和血管炎症中的作用.
- 确定内皮特异性SMAD4删除对高血压发展和血管功能的影响.
主要方法:
- 使用Tie2-Cre/ERT2系统生成内皮特异性的Smad4淘汰赛 (EC-Smad4 KO) 鼠标.
- 通过血管素II (Ang II) 输液诱导高血压,并使用线筋图评估血管功能.
- 分析了基因表达,氧化 (NO),活性氧物种 (ROS) 和内 плазма网膜 (ER) 压力标志物.
主要成果:
- EC-Smad4 KO小鼠表现出降低Ang II诱导的血压升高和改善内皮依赖放松.
- 在EC-Smad4 KO小鼠中,Ang II诱导的ROS生成和VCAM1表达被抑制.
- 删除Smad4减少了p38 MAPK酸化,增加了p-eNOS,并减少了ER压力标志物.
结论:
- 在高血压中,Smad4信号传递是内皮功能障碍和血管炎症的关键调解者.
- 内皮特异性的Smad4删除改善了血管功能障碍.
- 这种保护作用是通过减少氧化应激,ER应激和血管炎症来实现的.
相关概念视频
Hypertension II: Pathophysiology
88
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
88
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
513
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
513

